My heart goes out to all holders. This is a biotech investor's worst nightmare, seeing the flagship product dropped. Here's hoping their cash reserves can come up with a winner in the end. Gotta agree with Swuzz though, they could do a lot worse than drop $6m into SLA and pick up ANZ's 20m share overhang. Would need to be quick though.
